|
業務類別
|
-- |
|
業務概覽
|
WuXi Biologics is one of the largest global biologic global contract development and manufacturing organizations. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 18.7 billion. North America represented 57.3% of total revenue in 2024. The firm has a "follow and win the molecule" strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual sourcing strategy by providing drug products and drug substance manufacturing. |
| 公司地址
| No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092 |
| 電話號碼
| +86 51085353482 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.wuxibiologics.com |
| 員工數量
| 12575 |
| Dr. Zhisheng Chen |
Chief Executive Officer and Director |
-- |
29/04/2025 |
|
|
| Mr. William Robert Keller |
Independent Director |
29/04/2025 |
| Mr. Jackson Peter Tai |
Independent Director |
29/04/2025 |
| Mr. Yanling Cao |
Director |
29/04/2025 |
| Mr. Kenneth Walton Hitchner, III |
Independent Director |
29/04/2025 |
| Ms. Jingwen Miao |
Director |
29/04/2025 |
| Dr. Zhisheng Chen |
Chief Executive Officer and Director |
29/04/2025 |
| Dr. Ge Li |
Chairman of the Board |
29/04/2025 |
| Dr. Jue Chen |
Independent Director |
29/04/2025 |
| Dr. Weichang Zhou |
Director |
29/04/2025 |
|
|
|
|
